IFNB1 and myeloid sarcoma: By analyzing a cohort with extended follow-up, our study captures a historical MS population largely exposed to moderately effective DMTs, mainly interferon-beta products, mirroring the training and validation population of the RoAD score [7] and offering a representative picture of patients traditionally treated with therapies of limited immunologic effect as the first approved DMTs.